CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Stellar Biotechnologies Inc. (OLD) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Stellar Biotechnologies Inc. (OLD)
332 E Scott Street
Phone: (805) 488-2800p:805 488-2800 PORT HUENEME, CA  93041  United States Fax: (805) 488-2889f:805 488-2889
This company is no longer actively traded on any major stock exchange.
Business Summary
Stellar Biotechnologies, Inc. (Stellar) is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH) protein. KLH is a high molecular weight and immune-stimulating protein. It operates under the brand name Stellar KLH. Its products include Stellar KLH protein in various grades, formulations and configurations for both clinical and preclinical applications. Stellar KLH can be used for therapeutic vaccine conjugation, as a carrier molecule in immunotherapies and as an immune stimulant in immunotoxicology applications. KLH can be used as an active pharmaceutical ingredient and combined with a disease-targeting agent to create immunotherapies targeting cancer, immune disorders, Alzheimer's disease and inflammatory diseases, or it can be used as a finished, injectable product in the immunodiagnostic market for measuring immune response in patients and research settings.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20159/30/2015Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Frank R.Oakes 65 1/1/2014 4/9/2010
Chief Financial Officer, Secretary KathiNiffenegger 58 11/5/2013 7/14/2013
Chief Operating Officer CatherineBrisson 42 11/5/2013 11/5/2013
5 additional Officers and Directors records available in full report.

Business Names
Business Name
CAG Capital Inc.
China Growth Capital Inc

General Information
Stock Exchange: CVE
Fax Number: (805) 488-2889


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023